Vaxart Inc

-0.06 (-2.52%)

Vaxart Announces Phase 2 Clinical Study Data Of Wuhan S-Only Covid-19 Pill Vaccine Candidate

Published: 09/01/2022 11:52 GMT
Vaxart Inc (VXRT) - Vaxart Announces Positive Top-line Phase Ii Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-only Covid-19 Pill Vaccine Candidate.
Vaxart Inc - Study Met Primary Safety and Secondary Immunogenicity Endpoints.
Vaxart - Reported Positive Top-line Data From First Part of Two-part Phase Ii Study of Wuhan S-only Oral Pill Covid-19 Vaccine Candidate, Vxa-cov2-1.1-s.
Vaxart Inc - Vxa-cov2-1.1-s Vaccine Construct Was Safe and Well-tolerated.
Vaxart Inc - No Vaccine-related Solicited Grade 3 Adverse Events (aes) and No Vaccine-related Serious Adverse Events (saes) Were Reported.
Vaxart - About 50% of All Subjects, and 50% of Subjects That Previously Received Mrna Vaccine, Had at Least 1.5-fold Increase in Mucosal Iga Antibodies.